Keystone Nano
| Company type | Private |
|---|---|
| Industry | Nanotechnology, Biotechnology |
| Founded | 2005 |
| Headquarters | Pennsylvania , United States |
| Products | Nanoscale technologies for diagnosing and treating human illnesses |
Keystone Nano, established in 2005, is a U.S.-based enterprise located in Pennsylvania that focuses on developing nanoscale technologies aimed at diagnosing and treating human illnesses to enhance overall well-being.
Patents
The company and its research team possess significant patents, such as:
- US Patent (8,747,891) – Awarded to The Penn State Research Foundation along with Keystone Nano's Chief Medical Officer, Mark Kester, this patent pertains to a method for incorporating ceramide nanoscale liposomes with anti-cancer agents. This advancement improves targeted tumor delivery and extends the therapeutic duration by combining the effects of ceramide and cancer-fighting compounds.
FDA Approval
In January 2017, Keystone Nano received FDA authorization for its investigational new drug application involving NanoLiposome intended for solid tumor treatment. Subsequently, Phase 1 clinical studies commenced at institutions including the University of Maryland, University of Virginia, and Medical University of South Carolina.
Compound
The FDA granted Keystone Nano permission in 2017 to initiate clinical testing of ceramide nanoliposome as a novel therapeutic option against cancer.